CBNGO00041: Precision tools for glycoprotein research and precision medicine 1072108-06-5

Glycan Oxazoline, as a key structural unit in glycobiology, is promoting innovation in glycoprotein engineering and carbohydrate drug development. Among them, CBNGO00041, with its high complexity and specificity, has become a core molecule for synthesizing uniform glycoconjugates and deciphering the biological functions of glycosylation, providing new ways for disease intervention and treatment strategies.

Chemical Information

Chemical name: 2-methyl-[beta-D-galactopyranosyl-(1->4)-beta-D-glucopyranosyl-(1->6)-alpha-D-mannopyranosyl-(1->3)-[beta-D-galactopyranosyl-(1->4)-b eta-D-glucopyranosyl-(1->6)-alpha-D-mannopyranosyl-(1->6)]-beta-D-mannopyranosyl-(1->4)-1,2-deoxy-alpha-D-glucopyrano]-[2,1-d]-2-oxazoline

Generic name: Glycan Oxazoline

Chemical formula: C50H83NO40

Molecular weight: 1338.18 g/mol

CAS number: 1072108-06-5

Structural features

CBNGO00041 is a highly branched oligosaccharide derivative whose structure integrates glycosyl oxazetidine rings and precisely arranged sugar units, exhibiting unique chemical and biophysical properties:

Complex sugar chain structure: It is composed of galactose, glucose, and mannose connected through various glycosidic bonds such as β-(1→4), β-(1→6), and α-(1→3), simulating the N-linked glycan core structure in natural glycoproteins. This multivalency and branching enhances the specificity of interactions with proteins such as lectins and antibodies, providing an ideal model for studying the sugar-protein recognition mechanism.

Stable oxazetidine ring: The 2-oxazetidine ring at the end of the molecule is connected to the sugar group through C-N bonds to form a highly reactive intermediate. This ring can be specifically activated by glycosidase or chemical reagents under mild conditions, achieving efficient coupling with protein amino acid side chains (such as asparagine), and is suitable for controllable glycoprotein synthesis.

Stereochemical accuracy: All sugar units exist in the D configuration and specific anomeric carbon configuration (α or β), ensuring compatibility with glycosylases and receptors in biological systems. This structural precision helps reduce non-specific binding and improve targeting capabilities in drug design.

Main applications and advantages

Key intermediates for glycoprotein chemoenzymatic synthesis

In glycoprotein engineering, uniform glycosylation is central to maintaining protein stability, immunogenicity, and function. As an activated glycosyl donor, CBNGO00041 can site-specifically graft well-defined oligosaccharide chains to the protein backbone through a glycosidase-mediated transglycosylation reaction. This method overcomes the limitations of cumbersome steps and low yields of traditional chemical synthesis, provides an efficient platform for the production of uniform glycoprotein drugs (such as monoclonal antibodies, enzyme replacement therapy preparations), and promotes the development of treatments for cancer, autoimmune diseases and other fields.

Molecular probes for disease-related glycosylation studies

Aberrant glycosylation is closely associated with cancer progression, pathogenic infections, and neurodegenerative diseases. The complex sugar chain structure of CBNGO00041 can simulate tumor-related antigens (such as Tn antigen or sialoglycan) and be used to develop detection reagents or inhibitors to decipher the role of glycosylation in cell signal transduction and immune evasion. In addition, the derivatization potential of its oxazetidine ring allows the introduction of fluorescent or biotin tags to achieve dynamic visualization of glycoproteins in living cells or tissues, assisting biomarker discovery and diagnostic tool innovation.

Building blocks for carbohydrate drug and vaccine development

Sugar-based vaccines (such as antibacterial polysaccharide vaccines) and targeted drugs rely on structurally well-defined sugar antigens to elicit specific immune responses. The highly branched oligosaccharide framework of CBNGO00041 can be used as a carrier to connect adjuvants or proteins by modifying the oxazetidine ring to construct multivalent glycoconjugate vaccines to enhance immunogenicity and memory responses. At the same time, its sugar chain diversity supports customized design for the development of immunotherapies targeting specific pathogens (such as HIV, malaria) or cancer neoantigens, reducing off-target risks and optimizing pharmacokinetic properties.

Conclusion

CBNGO00041 represents a milestone in glycoscience moving towards precise application. From deciphering the glycosylation code to designing next-generation biologics, its structural versatility and biocompatibility open new horizons for glycobiology research, diagnostic innovation, and therapeutic development. With the integration of synthetic biology and medicinal chemistry, these molecules will continue to empower infectious disease prevention and control, tumor immunotherapy and rare disease management, leading to a new era of glycosylation-oriented medical treatment.

The above information is provided by the editor of KASONS and is for scientific research only.